Chevallard Daniel R.
CIK 0001706176
Chief Financial Officer
Filings
16
Latest Mar 30, 2026
Issuers covered
2
Showing
16 of 16
Page 1
Track record
3 of 11 open-market trades scored (27% price coverage) - 8 issuers without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 3 | 100% | +17.0% | +16.3% | +18.5% | +16.3% |
| 90 days | 3 | 33% | -10.3% | -39.2% | +47.5% | -39.2% |
| 180 days | 3 | 33% | +3.9% | -57.9% | +127.4% | -57.9% |
| 365 days | 1 | 100% | +75.8% | +75.8% | +75.8% | +75.8% |
Issuers
Companies where Chevallard Daniel R. has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| VIRX | Viracta Therapeutics, Inc. | 10 | Mar 13, 2024 |
| GRPH | Graphite Bio, Inc. | 6 | Mar 30, 2026 |
All filings
16 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|